Statement: The median TTP in cohort one of the primary trial is just under 27 months.
Primary_evidence: Outcome Measurement:    Time to Progression (TTP)   Time to progression is defined as the time from treatment start until objective tumor progression. Progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion, progression of existing non-target lesions, or the appearance of 1 or more new lesions. The median time to progression is the parameter used to describe TTP.   Time frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks), up to 29 months. Results 1:    Arm/Group Title: Capecitabine and Fulvestrant   Arm/Group Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of   80 kg.   Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days.   Overall Number of Participants Analyzed: 41   Median (95% Confidence Interval)   Unit of Measure: Months  26.94  [1]    (7.26 to NA)